BENGALURU, July 19 (Reuters) - Indian pharmaceutical
firm Jubilant Pharmova JUBA.NS reported a nearly four-fold
rise in first-quarter adjusted profit on Friday, boosted by
strong demand for its drugs that contain radioactive
ingredients.
The company's consolidated net profit before exceptional
items and taxes rose to 1.04 billion rupees ($12.4 million) in
the three months ended June 30 from 252 million rupees a year
earlier.
The company had a one-time gain of 3.96 billion rupees after
the sale of one of its units in the United States.
The company's shares rose as much as 10% after the results
to a three-year high of 800 rupees, before paring most of the
gains.
Analysts expect consistent growth in the company's
high-margin radiopharma segment to drive revenue growth.
Jubilant Pharmova is involved in the manufacturing and
supply of radiopharmaceuticals with a network of 46
radio-pharmacies in the United States. The company said it will
invest $50 million to add six sites in its radiopharmacy
network.
Total revenue rose 9% to 17.32 billion rupees, lifted by a
20.5% rise in the radiopharma segment. The business, which
involves developing radioactive medications used to diagnose or
treat cancer, accounted for more than 48% of the total revenue.
Revenue from its contract manufacturing segment, its
second-biggest, also climbed 13% to 3.34 billion rupees.
($1 = 83.6250 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru; Editing by
Subhranshu Sahu and Sohini Goswami)
((Kashish.Tandon@thomsonreuters.com; 8800437922;))